On The Organ Trail: Bristol-Myers Wins An SPA For Kidney Transplant Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug maker offers an upbeat prognosis on clinical data heading into a crucial medical conference late next month
You may also be interested in...
Transplant Rejection Rate Will Be Pivotal Part Of Panel Review For Bristol's Belatacept
Additional challenges include displacing standard of care, reimbursement and route of administration.
Transplant Rejection Rate Will Be Pivotal Part Of Panel Review For Bristol's Belatacept
Additional challenges include displacing standard of care, reimbursement and route of administration.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.